QuidelOrtho (NASDAQ:QDEL) Rating Increased to Buy at Wall Street Zen
Wall Street Zen has upgraded QuidelOrtho (NASDAQ:QDEL) from "hold" to "buy," despite a mixed consensus from other analysts, resulting in an average "Reduce" rating and a $31.50 price target. The company recently surpassed quarterly earnings and revenue estimates, reporting $0.46 EPS and $723.6M revenue. Additionally, insider buying activity by the CFO and a director suggests confidence, with significant share purchases totaling approximately $568k.
QuidelOrtho Corp Stock: Navigating Diagnostics Leadership Amid Sector Evolution and Investor Opportu
QuidelOrtho Corp (ISIN: US7476011036) is a significant entity in in vitro diagnostics, specializing in point-of-care testing and immunoassay markets. This analysis from early 2026 delves into its business model, competitive landscape, and strategic watchpoints. The company's dual-track approach featuring rapid diagnostics and lab-based assays, along with its focus on recurring revenue from consumables, positions it for continued growth amidst evolving healthcare demands and increasing decentralization of care. While facing competition from industry giants, QuidelOrtho leverages its technological edge and strategic initiatives, though regulatory hurdles and supply chain vulnerabilities remain key watchpoints for investors.
QuidelOrtho Corp. Stock Plummets to New 52-Week Low of $14.45
QuidelOrtho Corp., a small-cap player in the Pharmaceuticals & Biotechnology sector, has hit a new 52-week low of $14.45, marking a significant 64.06% decline in its 1-year performance. The company has faced negative financial results for 12 consecutive quarters, a high debt-equity ratio of 1.31, and a consistent underperformance compared to the S&P 500. This plummet reflects ongoing difficulties and a challenging year for the company.
Vanguard disaggregates holdings; reports 0 shares of QuidelOrtho (QDEL)
Vanguard Group has filed an amended Schedule 13G/A for QuidelOrtho (QDEL), reporting zero beneficial ownership of common stock. This change is due to an internal realignment where certain subsidiaries will now report their ownership separately, as per SEC Release No. 34-39538. Previously, these holdings were aggregated under The Vanguard Group, which now disclaims beneficial ownership of shares held by these subsidiaries.
Precision Trading with Quidelortho Corp Com (QDEL) Risk Zones
This article analyzes Quidelortho Corp Com (QDEL) with a short bias due to weak sentiment across all horizons, indicating a breakdown is underway. It provides three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry zones, targets, and stop losses. The analysis also includes multi-timeframe signal analysis, showing weak signals across near-term, mid-term, and long-term horizons, and highlights elevated downside risk.
QuidelOrtho Corporation (NASDAQ:QDEL) Given Average Recommendation of "Reduce" by Brokerages
QuidelOrtho Corporation (NASDAQ:QDEL) has received an average "Reduce" rating from six brokerages, with a 12-month average price target of $31.50. Despite this, recent insider activity shows the CEO and CFO purchasing shares. The company reported better-than-expected Q4 earnings with revenue up 2.2% year-over-year, but still faces a negative net margin and PE ratio.
Medtech business QuidelOrtho hires STAAR Surgical legal head as CLO
QuidelOrtho, a US medtech company, has appointed Nathaniel Sisitsky as its new Chief Legal Officer, succeeding the retiring Michelle Hodges. Sisitsky brings over 25 years of legal experience in life sciences and technology, joining from STAAR Surgical where he also served as CLO. He will be responsible for leading QuidelOrtho's global legal, compliance, and corporate governance functions.
QuidelOrtho names Nathaniel Sisitsky as chief legal officer By Investing.com
QuidelOrtho Corporation (NASDAQ:QDEL) has appointed Nathaniel Sisitsky as Chief Legal Officer, effective Monday, replacing Michelle Hodges, who is retiring. Sisitsky brings over 25 years of legal and governance experience in life sciences and technology sectors. The appointment comes as QuidelOrtho faces financial challenges, with its shares significantly down and the company carrying substantial debt, though analysts predict a return to profitability this year.
QuidelOrtho (QDEL) Welcomes New Chief Legal Officer
QuidelOrtho (QDEL) has appointed Nathaniel "Nate" Sisitsky as its new Chief Legal Officer, effective March 23, to lead the company's global legal, compliance, and corporate governance activities. Sisitsky brings over 25 years of experience in life sciences and technology sectors. Despite this leadership enhancement, the company faces significant financial challenges, including declining revenue, negative profitability margins, high leverage, and a distress-level Altman Z-Score, suggesting potential bankruptcy risk.
In Vitro Diagnostics Firm QuidelOrtho Picks New Legal Chief
QuidelOrtho Corp., a leader in in vitro diagnostics, has appointed Nathaniel "Nate" Sisitsky as its new chief legal officer, effective March 24, 2026. Sisitsky brings over 25 years of legal and governance experience from the life sciences and technology sectors, having previously served as chief legal officer at STAAR Surgical Co. He succeeds Michelle Hodges, who is retiring.
In Vitro Diagnostics Firm QuidelOrtho Picks New Legal Chief
QuidelOrtho Corp., a global leader in in vitro diagnostics, has appointed Nathaniel "Nate" Sisitsky as its new chief legal officer, effective Monday. Sisitsky brings over 25 years of legal and governance experience, particularly within the life sciences and technology sectors, having most recently served as CLO at STAAR Surgical Co. He succeeds Michelle Hodges, who is retiring.
QuidelOrtho Announces Chief Legal Officer Leadership Transition
QuidelOrtho (QDEL) has announced a leadership transition for its Chief Legal Officer role. Michelle A. Hodges will retire effective March 23, 2026, and transition into an advisory role for up to 24 months to ensure continuity. Nathaniel “Nate” Sisitsky, a seasoned legal executive with over 25 years of experience in life sciences and medtech, has been appointed as the new Chief Legal Officer and Corporate Secretary.
QuidelOrtho names Nathaniel Sisitsky as chief legal officer
QuidelOrtho Corporation has appointed Nathaniel Sisitsky as its new Chief Legal Officer, effective Monday. Sisitsky, bringing over 25 years of legal and governance experience from the life sciences and technology sectors, will be responsible for the company's global legal, compliance, and corporate governance functions. This leadership change comes as QuidelOrtho faces financial challenges, including a 54% drop in share price over the past year and significant debt, although analysts predict a return to profitability this year.
QuidelOrtho hires ex-STAAR legal chief as Michelle Hodges retires
QuidelOrtho (Nasdaq: QDEL) has appointed Nathaniel "Nate" Sisitsky as its new Chief Legal Officer, effective March 23, 2026. Sisitsky brings over 25 years of legal experience in life sciences and technology, previously serving as Chief Legal Officer at STAAR Surgical. He succeeds Michelle Hodges, who is retiring but will remain in an advisory role during the transition.
Nathaniel Sisitsky Joins QuidelOrtho as Chief Legal Officer
QuidelOrtho Corporation has appointed Nathaniel "Nate" Sisitsky as its new Chief Legal Officer, effective March 23, 2026. Sisitsky brings over 25 years of legal and governance experience in life sciences and technology, previously serving as Chief Legal Officer at STAAR Surgical Company. He will lead QuidelOrtho's global legal, compliance, and corporate governance functions, succeeding Michelle Hodges, who is retiring.
QuidelOrtho (QDEL) Baird 2024 Global Healthcare Conference Summary
This article summarizes QuidelOrtho's presentation at the Baird 2024 Global Healthcare Conference, highlighting the stability and growth of its Labs segment, CEO transition, and strategic shift towards integrated instruments. The company focuses on cost realignment, continuous improvement, and capitalizing on geographic opportunities like China. It also provides a brief overview of recent financial events and guidance for QuidelOrtho.
QuidelOrtho (QDEL) Morgan Stanley’s 22nd Annual Global Healthcare Conference summary
QuidelOrtho's summary from Morgan Stanley's 22nd Annual Global Healthcare Conference highlights strategic shifts towards cost optimization, margin improvement, and renewed focus on customer satisfaction. Key drivers for future growth include stable Labs business with expected mid-single-digit growth in H2 2024, continued expansion in immunoassay share, and development in STI testing and menu expansion for the Savanna platform. The company also noted sustained high single-digit growth in its China business.
QuidelOrtho (QDEL) 43rd Annual J.P. Morgan Healthcare Conference 2025 Summary
QuidelOrtho (QDEL) presented a summary of its operations and growth strategies at the 43rd Annual J.P. Morgan Healthcare Conference in 2025. The company detailed its market positioning across various diagnostic sectors, global reach, and leadership changes aimed at efficiency and innovation. Key growth drivers include its Labs business, Molecular Diagnostics with the Savanna platform, and a comprehensive product portfolio serving multiple care settings.
QDEL SEC Filings - Quidel 10-K, 10-Q, 8-K Forms
This page provides access to QuidelOrtho Corporation's SEC filings, including 10-K, 10-Q, and 8-K forms, offering comprehensive regulatory documents for investors. It highlights recent insider transactions, such as CFO Joseph Busky's RSU vesting and executive equity awards, and details major ownership changes like FMR LLC's 8% stake. The platform also notes board changes and provides AI-powered summaries for quick understanding of these complex financial disclosures.
QDEL SEC Filings - Quidel 10-K, 10-Q, 8-K Forms
This article provides a comprehensive overview of QuidelOrtho Corporation's (QDEL) SEC filings, including 10-K, 10-Q, and 8-K forms, accessible through the Stock Titan platform. It highlights how these filings inform investors about the company's financial condition, strategic decisions, and material events in the in vitro diagnostics and medical device manufacturing sector. The platform also offers AI-powered summaries to simplify complex regulatory documents for easier understanding.
QuidelOrtho Corp stock hits new 52-week low amid persistent financial struggles and biotech sector headwinds
QuidelOrtho Corp's stock has plummeted to a new 52-week low of $16.16 USD, reflecting 12 consecutive quarters of losses and high debt levels. The company, specializing in in-vitro diagnostics, faces significant financial strain as post-pandemic demand for COVID-19 tests wanes and integration costs from its merger with Ortho Clinical Diagnostics weigh heavily. Despite a low price-to-book ratio suggesting potential value, persistent losses and high short interest signal investor skepticism, necessitating a strong turnaround in earnings and debt reduction to reverse its prolonged downturn.
QuidelOrtho Corp. Hits Day Low of $16.16 Amid Price Pressure
QuidelOrtho Corp., a Pharmaceuticals & Biotechnology sector company, experienced significant stock volatility, hitting an intraday low of $16.16, with a year-to-date decline of nearly 42%. The company's financial performance is concerning, marked by a high debt-equity ratio and negative return on equity. These figures highlight the ongoing challenges QuidelOrtho faces in the market.
QuidelOrtho Corp. Stock Plummets to New 52-Week Low at $17.03
QuidelOrtho Corp. reached a new 52-week low of $17.03 on March 18, 2026, marking a significant decline of 58.58% over the past year. The company, with a market capitalization of USD 1,202 million, has reported negative results for 12 consecutive quarters and has a high debt-equity ratio of 1.31. Its performance considerably lags the S&P 500's gain of 17.99% over the same period, indicating ongoing financial challenges.
RBC Capital Raises PT on QuidelOrtho Corporation From $60 to $62, Keeps Buy Rating
RBC Capital has increased its price target for QuidelOrtho Corporation (QDEL) from $60 to $62, while maintaining a Buy rating on the stock. This adjustment reflects continued confidence in the company's performance and future outlook from the analyst firm.
RBC Capital Raises PT on QuidelOrtho Corporation From $60 to $62, Keeps Buy Rating
RBC Capital has increased its price target for QuidelOrtho Corporation (QDEL) from $60 to $62, while maintaining a Buy rating on the stock. This adjustment reflects continued confidence in the company's financial outlook and market position. The decision by RBC Capital suggests a positive long-term view for QuidelOrtho.
QuidelOrtho (NASDAQ:QDEL) Trading Down 8.3% - Should You Sell?
QuidelOrtho (NASDAQ:QDEL) shares dropped 8.3% to $17.54 on Wednesday, trading significantly below average volume. Analyst sentiment is generally bearish, with a consensus "Reduce" rating and an average price target of $31.50, despite the company slightly beating EPS and revenue estimates but reporting a large negative net margin. Insiders, including the CEO and CFO, have recently purchased shares, indicating some internal confidence.
QuidelOrtho Corp. Hits Day High with Strong 8.33% Intraday Surge
QuidelOrtho Corp., a small-cap pharmaceutical company, saw its stock surge by 8.33% to an intraday high of USD 19.72, despite a year of significant decline (47.18%) and poor financial metrics. The company has a high debt-equity ratio, low interest coverage, and negative return on equity, indicating ongoing challenges. Today's rise offers a brief positive interlude amidst continuous underperformance compared to the S&P 500.
QuidelOrtho Corp Stock (ISIN: US7476011036) Faces Institutional Shifts Amid Diagnostics Recovery Signals
QuidelOrtho Corp (ISIN: US7476011036) stock is trading at $17.10, showing mixed institutional activity with some firms acquiring shares and others selling, amid a backdrop of post-pandemic challenges in diagnostics. UBS maintains a $30 price target, signaling over 75% upside potential despite the company's ongoing losses. European investors are viewing QuidelOrtho as a value play with long-term recovery potential driven by its diagnostics installed base and consumables business model.
QuidelOrtho Corporation $QDEL Shares Acquired by Aristotle Capital Boston LLC
Aristotle Capital Boston LLC significantly increased its stake in QuidelOrtho Corporation (NASDAQ:QDEL) by 62.4% in the third quarter, acquiring an additional 146,956 shares. This investment signals institutional confidence, further reinforced by recent insider purchases from the CEO and CFO. Despite this, analyst sentiment remains mixed, with a consensus "Reduce" rating and a target price of $31.50 for the diagnostic solutions company.
ArrowMark Colorado Holdings LLC Sells 181,325 Shares of QuidelOrtho Corporation $QDEL
ArrowMark Colorado Holdings LLC reduced its stake in QuidelOrtho Corporation by 18.8% in the third quarter, selling 181,325 shares and now owning 782,954 shares valued at $23.06 million. Despite this, company insiders, including CFO Joseph M. Busky and Director Matthew Strobeck, increased their holdings. QuidelOrtho exceeded revenue and EPS estimates but reported a negative net margin, with Wall Street maintaining a "Reduce" rating and a $31.50 price target.
QuidelOrtho Corp. Experiences Revision in Stock Evaluation Amid Market Challenges
QuidelOrtho Corp. has undergone a stock evaluation revision due to challenging market conditions, with its price at $17.92, reflecting a 51.40% decline over the past year against the S&P 500's rise. Technical indicators are predominantly bearish, and the stock has dropped 86.84% over five years, highlighting significant struggles in the pharmaceuticals and biotechnology sector.
American Century Companies Inc. Raises Stock Position in QuidelOrtho Corporation $QDEL
American Century Companies Inc. increased its stake in QuidelOrtho Corporation (NASDAQ:QDEL) by 10.4% in the third quarter, now owning over 2.1 million shares valued at approximately $62.3 million. Insiders also showed increased confidence, with CEO Brian J. Blaser and Director Matthew Strobeck acquiring a total of 20,540 shares in February. Despite beating Q3 earnings estimates with EPS of $0.46 and revenue of $723.6 million, QuidelOrtho faces a "Reduce" consensus rating from analysts with an average target price of $31.50.
QuidelOrtho Stock Challenges: Revenue, Cash Flow, and ROIC Trends - News and Statistics
Shares of QuidelOrtho have underperformed the S&P 500, showing a significant decline over the past six months due to concerns about revenue, cash flow, and return on invested capital. Analysts point to year-on-year revenue declines, negative free cash flow margins, and decreasing ROIC as major red flags. Despite a recent share price drop, the stock’s valuation is still considered to reflect optimistic expectations, suggesting better investment opportunities elsewhere.
A Look At QuidelOrtho (QDEL) Valuation After New Lifotronic Supply Agreement
QuidelOrtho (QDEL) recently announced a new long-term supply agreement with Lifotronic Technology, giving it access to additional immunoassay analyzers and assays in select international markets. Despite recent stock gains, longer-term momentum has been weak, with a 1-year total shareholder return decline of 41.77%. Simply Wall St analysts suggest the stock is undervalued by 34.4%, with a fair value of $34.67 per share, speculating on future growth from international market expansion, although challenges like declining COVID testing remain.
Segall Bryant & Hamill LLC Sells 71,044 Shares of QuidelOrtho Corporation $QDEL
Segall Bryant & Hamill LLC reduced its stake in QuidelOrtho Corporation by 5.5% in the third quarter, selling 71,044 shares and now holding 1,229,152 shares valued at $36.2 million. Despite beating earnings estimates with EPS of $0.46 and revenue of $723.6 million, QuidelOrtho reported a negative net margin and a "Reduce" consensus rating with a $31.50 target. Insider buying has occurred, with CEO Brian Blaser and CFO Joseph Busky purchasing shares, but institutional investors and hedge funds still own 99.00% of the company's stock.
A Look At QuidelOrtho (QDEL) Valuation After New Lifotronic Supply Agreement
QuidelOrtho (QDEL) recently announced a long-term supply agreement with Lifotronic Technology, giving it access to additional immunoassay analyzers and assays in international markets. Despite a recent 7.31% gain, the stock has shown weak long-term momentum with a 41.77% decline over the past year. Simply Wall St's analysis suggests QuidelOrtho is 34.4% undervalued, with a fair value of $34.67 per share, based on its potential for global expansion in diagnostics and improved future earnings, though challenges like declining COVID testing remain.
QuidelOrtho (QDEL): Buy, Sell, or Hold Post Q4 Earnings?
This article analyzes QuidelOrtho (QDEL) following its Q4 earnings, advising investor caution despite a recent stock price decline. The report highlights three key concerns: declining constant currency revenue, a dropping free cash flow margin, and a decrease in Return on Invested Capital (ROIC). The author suggests that at 10.5x forward P/E, the stock's valuation already prices in too much good news and recommends looking for more timely opportunities elsewhere.
A Look At QuidelOrtho (QDEL) Valuation After New Lifotronic Supply Agreement
QuidelOrtho (QDEL) recently announced a long-term supply agreement with Lifotronic Technology, which has brought fresh investor attention to the company. Despite a recent 7-day share price gain, longer-term momentum has been weak, with the stock currently trading at US$22.74 after a 1-year total shareholder return decline of 41.77%. Simply Wall St's most popular narrative suggests QuidelOrtho is 34.4% undervalued, with a fair value pegged at $34.67 per share, driven by expectations of global scaling for its diagnostics portfolio, particularly in international markets like Latin America and Asia Pacific.
Vanguard Group Inc. Has $224.89 Million Stock Position in QuidelOrtho Corporation $QDEL
Vanguard Group Inc. reduced its stake in QuidelOrtho Corporation (NASDAQ:QDEL) by 2.1% in the third quarter, now holding 7,636,193 shares valued at approximately $224.89 million. Despite beating quarterly earnings estimates, QuidelOrtho reported a negative net margin, and analysts maintain a "Reduce" rating with an average price target of $31.50. Recent insider activity shows CEO Brian J. Blaser and CFO Joseph M. Busky acquiring shares, though insiders collectively own less than 1% of the company.
QuidelOrtho Corp reports results for the quarter ended March 31 - Earnings Summary
QuidelOrtho Corp (QDEL) reported adjusted earnings of 74 cents per share for the quarter ended March 31, exceeding analyst expectations of 59 cents. Revenue decreased by 2.6% year-over-year to $692.80 million, though it surpassed analyst estimates. The company's shares have fallen significantly this quarter and year-to-date, despite a "buy" average analyst rating with a median 12-month price target of $54.00.
QuidelOrtho Corporation (NASDAQ:QDEL) Receives Average Recommendation of "Reduce" from Brokerages
QuidelOrtho Corporation (NASDAQ:QDEL) has received an average "Reduce" recommendation from brokerages, with a consensus 12-month price target of $31.50. Despite this, insiders, including the CEO and a director, have recently purchased shares, increasing insider ownership. The company also surpassed quarterly earnings and revenue estimates but reported negative net margins and a negative P/E ratio, indicating ongoing profitability challenges.
Should QuidelOrtho’s (QDEL) Lifotronic Immunoassay Expansion Require Action From QDEL Investors?
QuidelOrtho (QDEL) recently announced a long-term supply agreement with Lifotronic Technology to expand its immunoassay offerings in select markets outside the U.S. This deal aims to broaden its international diagnostics solutions, helping the company compete for full-menu tenders and serve a wider range of laboratories. While the agreement strengthens its immunoassay offerings, investors should consider the broader context of QuidelOrtho's strategy to stabilize non-COVID revenues and address ongoing unprofitability and leadership transitions.
Has QuidelOrtho (QDEL) Become A Potential Opportunity After Its Sharp Share Price Slide
QuidelOrtho (QDEL) has experienced a significant share price decline, making valuation a critical factor for investors. This article uses Discounted Cash Flow (DCF) and Price-to-Sales (P/S) analyses to assess its current valuation. Both methods suggest QuidelOrtho is currently undervalued, with the DCF model indicating a 73.9% undervaluation and the P/S ratio also pointing to an undervalued status compared to industry averages and its Fair Ratio.
QuidelOrtho terminates CEO
QuidelOrtho has terminated its President and CEO, Douglas Bryant, effective immediately, following a comprehensive evaluation by the board of directors. Michael Iskra has been appointed interim CEO and Robert Bujarski as interim president. The company's board has initiated a search for a new CEO, considering both internal and external candidates, and reaffirmed its financial guidance provided on February 16.
Faster Cardiac Answers with High‑Sensitivity Troponin
QuidelOrtho Corporation has released a new Science Bytes podcast episode focusing on how high-sensitivity troponin (hs troponin) is revolutionizing early cardiac diagnosis and improving emergency department efficiency. The podcast highlights its ability to detect cardiac injury earlier, provide precise and reproducible results, enable faster rule-out protocols, and ensure more equitable care with sex-specific cutoffs. Emerging research is also exploring broader applications for hs troponin in various medical fields.
QuidelOrtho (NASDAQ:QDEL) Rating Lowered to Strong Sell at Zacks Research
Zacks Research downgraded QuidelOrtho (NASDAQ:QDEL) from a "hold" to a "strong sell" rating. The company's stock opened at $24.16, and analysts predict earnings per share of $2.3 for the current fiscal year. Insider transactions show CFO Joseph M. Busky and Director Matthew Strobeck recently increased their holdings in the company's stock.
QuidelOrtho Corp SEC 10-K Report
QuidelOrtho Corp has released its annual Form 10-K report, detailing a 2% decrease in total revenues to $2,730.2 million, primarily due to reduced COVID-19 related sales, resulting in a net loss of $(1,131.8) million. The company is implementing an Optimization Plan for cost-reduction and refocusing its Molecular Diagnostics business while facing challenges from industry competition, global market conditions, and regulatory risks. Future strategies include R&D investment, strategic acquisitions, and enhancing recurring revenue through a reagent rental model.
QuidelOrtho to Present at the 47th Annual Raymond James Institutional Investor Conference
QuidelOrtho Corporation announced that its management team will present at the Raymond James 47th Annual Institutional Investor Conference on March 3, 2026, at 1:40 p.m. ET. Interested parties can access the live webcast and replay through the "Events & Presentations" section of QuidelOrtho's investor relations website. The company is a global leader in innovative in vitro diagnostics, dedicated to advancing diagnostics for a healthier future.
QuidelOrtho to Present at the 47th Annual Raymond James Institutional Investor Conference
QuidelOrtho Corporation (Nasdaq: QDEL), a leader in in vitro diagnostics, announced that its management team will present at the 47th Annual Raymond James Institutional Investor Conference. The presentation is scheduled for Tuesday, March 3, 2026, at 1:40 p.m. ET, and will be accessible via webcast on the company's investor relations website. The company aims to advance diagnostics for a healthier future with its expertise in various testing methods.
The Top 5 Analyst Questions From QuidelOrtho's Q4 Earnings Call
QuidelOrtho's Q4 2025 results showed improved operational efficiency and growth in core labs, but the market reacted negatively due to declining respiratory revenues, tariffs, and a product mix that pressured gross margins. During the earnings call, analysts focused on the sustainability of Labs growth, potential impacts of China's VBP changes, reasons for wide EPS guidance, gross margin softness, and the near-term growth impact of new diagnostics. Management addressed these concerns by highlighting cost savings, international market opportunities, and the complexities of forecasting in a volatile environment.
